WO2004040969A1 - Ganp導入トランスジェニック哺乳動物及びその利用 - Google Patents
Ganp導入トランスジェニック哺乳動物及びその利用 Download PDFInfo
- Publication number
- WO2004040969A1 WO2004040969A1 PCT/JP2002/011598 JP0211598W WO2004040969A1 WO 2004040969 A1 WO2004040969 A1 WO 2004040969A1 JP 0211598 W JP0211598 W JP 0211598W WO 2004040969 A1 WO2004040969 A1 WO 2004040969A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cells
- ganp
- gene
- mice
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title claims abstract description 58
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 42
- 101710194542 Germinal-center associated nuclear protein Proteins 0.000 claims abstract description 100
- 238000000034 method Methods 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 119
- 239000000427 antigen Substances 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 56
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 15
- 101100379060 Amorphotheca resinae GAMP gene Proteins 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 7
- 230000008569 process Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 86
- 102100037412 Germinal-center associated nuclear protein Human genes 0.000 description 76
- 108090000623 proteins and genes Proteins 0.000 description 60
- 241000699666 Mus <mouse, genus> Species 0.000 description 31
- 210000000952 spleen Anatomy 0.000 description 26
- 239000013598 vector Substances 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 230000003053 immunization Effects 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- 238000002649 immunization Methods 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 18
- 210000001280 germinal center Anatomy 0.000 description 18
- 210000001165 lymph node Anatomy 0.000 description 15
- 235000013601 eggs Nutrition 0.000 description 14
- 238000003018 immunoassay Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000007790 solid phase Substances 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000002372 labelling Methods 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 102000016559 DNA Primase Human genes 0.000 description 10
- 108010092681 DNA Primase Proteins 0.000 description 10
- 108700019146 Transgenes Proteins 0.000 description 10
- 229960002685 biotin Drugs 0.000 description 10
- 239000011616 biotin Substances 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 235000020958 biotin Nutrition 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000011830 transgenic mouse model Methods 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 229920001917 Ficoll Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 210000004180 plasmocyte Anatomy 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108010042685 trinitrophenyl keyhole limpet hemocyanin Proteins 0.000 description 8
- 206010069754 Acquired gene mutation Diseases 0.000 description 7
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 230000016784 immunoglobulin production Effects 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000037439 somatic mutation Effects 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108010090804 Streptavidin Proteins 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 4
- 101150026842 Anp gene Proteins 0.000 description 4
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 4
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 101001025774 Mus musculus Germinal-center associated nuclear protein Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009824 affinity maturation Effects 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 101100174782 Mus musculus Mcm3ap gene Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 230000036963 noncompetitive effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241001416090 Ardea cinerea Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000237988 Patellidae Species 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- UQCONOAQMLZQMP-IDIVVRGQSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol;potassium;sodium Chemical compound [Na].[K].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UQCONOAQMLZQMP-IDIVVRGQSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 101150118742 NP gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- WXAYTPABEADAAB-UHFFFAOYSA-N Oxyphencyclimine hydrochloride Chemical compound Cl.CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 WXAYTPABEADAAB-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010046016 Peanut Agglutinin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000010357 RNA editing Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102000003705 Syndecan-1 Human genes 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 235000010726 Vigna sinensis Nutrition 0.000 description 1
- 244000042314 Vigna unguiculata Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000008350 antigen-specific antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 108091007231 endothelial receptors Proteins 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009408 flooring Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001485 positron annihilation lifetime spectroscopy Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- YVSWPCCVTYEEHG-UHFFFAOYSA-N rhodamine B 5-isothiocyanate Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(N=C=S)C=C1C(O)=O YVSWPCCVTYEEHG-UHFFFAOYSA-N 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 231100000427 somatic mutation induction Toxicity 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 108010055746 trinitrophenyl-bovine serum albumin Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knockout animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Definitions
- the present invention relates to a transgenic mammal into which a GANAP gene has been introduced, and its use. More specifically, the present invention provides a transgenic mammal capable of producing a high-affinity antibody by highly expressing GANP, and a method for producing a high-affinity antibody using the transgenic mammal. , And the use of the obtained high affinity antibody.
- a transgenic mammal capable of producing a high-affinity antibody by highly expressing GANP
- a method for producing a high-affinity antibody using the transgenic mammal and the use of the obtained high affinity antibody.
- the function of the immune system is classified into a cellular immune response mainly based on the effect of T cells and a humoral immunity mainly based on the effect of antibodies. In practice, the functions of both cooperate to produce an immune response.
- Antibodies are expressed as cell surface receptors on B cells born in the bone marrow. Diversity to recognize the first antibodies formed in vivo is said to Ru top to 1 0 9-1 0 1 1 on the order, recognize any antigen determinants that may be present in the environment. However, the ability of these diverse antigen receptors to bind to antigens is generally low, often producing low-affinity antibodies, which do not provide a sufficient immune response.
- lymphocytes especially B cells / immunoglobulins (antibodies)
- kits for detecting antigens such as pathogens, diagnostics, and therapeutics.
- an antibody having high reactivity with the antigen hereinafter referred to as “high affinity antibody”
- high affinity antibody an antibody having high reactivity with the antigen
- the sensitivity to the antigen is excellent and the same dose is used.
- no means for increasing the affinity of the antibody has been known.
- An object of the present invention is to provide a high-affinity antibody effective as a diagnostic or therapeutic agent for various diseases, a transgenic mammal for producing the antibody, the high-affinity antibody or a highly affinity antibody-producing cell.
- the purpose is to provide the used drug.
- the present inventors first created a mouse lacking the GANAP gene so as to selectively delete B cells (Example 1). As a result, there was no effect on the development, differentiation and proliferation of cells of the immune system, and no significant change was observed in the total antibody production.
- the nitrophenyl group (NP group) which has been analyzed as a hapten, was combined with trigamma globulin (NP-CG), and the reaction of T cell-dependent antigen was examined. It is known that the reaction of C57BL / 6 mice to NP is performed in a single V region. It is known to be formed only by the V region of the IgG heavy chain of the antibody called VH18.2 and the lambda 1 gene.
- mice were generated that overexpress the GANP gene.
- a part of the human immunoglobulin gene intron enhancer was ligated to the 5 side and selectively expressed in B cells. This mouse is also born normally, There is no change in development, differentiation, or proliferation.
- the high affinity V region gene was significantly increased.
- transgenic mammal into which the GANAP gene has been introduced, its progeny, or a part thereof.
- the introduced GANAP gene is expressed in B cells.
- the transgenic mammal of the present invention is generated from ES cells transfected with the GANAP gene.
- a method for producing a high-affinity antibody which comprises administering an antigen to a transgenic mammal or a progeny thereof into which a GANAP gene has been introduced to produce an antibody.
- a high affinity antibody or a fragment thereof produced by the method for producing a high affinity antibody described above.
- an agent for diagnosing, treating or preventing a disease comprising the above-mentioned high affinity antibody or a fragment thereof.
- a human antibody or a fragment thereof comprising the V region of the above antibody.
- a drug comprising the above-mentioned humanized antibody or a fragment thereof.
- a high-affinity antibody-producing cell collected from the above-mentioned transgenic mammal or a progeny thereof to which an antigen has been administered.
- Figure 1 shows immunohistochemical analysis of autoimmune disease models MRL / lpr, NZB and normal C57BL / 6 using anti-GANP monoclonal antibody and ALP-conjugated anti-rat Ig antibody.
- the results performed on popliteal lymph nodes derived from female mice are shown.
- G AN P hi cells stained with VectorBlue (ALP substrate) has been observed in the lymph nodes of the MRL / lpr mice seven weeks, not observed in NZB mice of the same age, appeared to 40 weeks.
- FIG. 2 shows the appearance rate of GAN P hi cells in the popliteal lymph nodes of female NZB mice.
- pSer502 G ANP was detected with anti-pSer502 G AN P (PG / 103) monoclonal antibody (blue), all sections were stained with biotin-labeled anti-B220 monoclonal antibody, and then HRP-conjugated streptavidin and DAB (brown). Were detected in combination. Representative data from two independent experiments are shown.
- the scale bar is 100 // m.
- the lower panel shows the cell numbers of GAN P hi (black bars) and pSer502 GANP hi (dot bars) in the extrafollicular region during calo-age.
- Figure 3 shows the rate of appearance of the G AN P hi cells in the spleen of female NZB mice. Staining was performed as in FIG. Representative data from three independent experiments are shown. Scale bar is 100 ⁇ m.
- FIG. 4 shows the results of staining of spleen sections from multiple strains of mice with an anti-GAMP monoclonal antibody.
- GANP hi cells appeared prominently in the red pulp of MRL / lpr, NZB and B / WFK BXSB, but not in the spleen of NOD or BAI ⁇ c mice.
- FIG. 5 shows the identification of GANP hi cells in the red pulp of the spleen.
- Double staining of spleen sections of NZB mice using a biotin-labeled anti-B220 monoclonal antibody (left), a biotin-labeled anti-Syndecan-1 monoclonal antibody (middle), or a biotin-labeled anti-IgM monoclonal antibody (right), and GANP hi cells was identified. Stained cells doubly indicated by arrowheads, indicating that GANP hi cells are B220-Syndecari g M +. GANP expression is indicated by ALP (blue) and other markers are indicated by HRP (brown). Representative data from three independent experiments are shown.
- FIG. 6 shows the identification of plasma cell markers in GAN Phi cells.
- G AN P hi cells determine whether a proliferating plasma blasts were administered BrdU (lm g / mouse) to mice. Two hours later, the mice were killed and spleen sections were prepared. Sections were double-stained with anti-GA NP monoclonal antibody (blue) and anti-BrdU monoclonal antibody (red). GC shows germinal center (left). PAS staining was performed according to a conventional method. GANP single positive GANP hi cells are indicated by arrows, and PAS single positive cells are indicated by arrowheads (middle). The sections were stained with a biotin-labeled anti-CD-5 monoclonal antibody. The PALS region is shown (right). Representative data from three independent experiments are shown. The scale bar is 1 ⁇ ⁇ ⁇ .
- Figure 7 shows the expression of G AN P hi cells in the red pulp areas of the spleen of C57BL / 6 mice by TD- Ag immunization.
- Female C57BL / 6 mice (7 weeks old) were immunized intraperitoneally with TNP-Ficoll ( ⁇ -2-Ag) or TNP-KLH (TD-Ag), and spleens were obtained 14 days later.
- TNP KLH in immune mice showed induction of G AN P hi cells in the red pulp area (right).
- GANP hi cells are indicated by arrows.
- WP indicates the white pulp region. Scale bar is 100 ⁇ .
- Figure 8 shows somatic mutations of transfectants that stably expressed mouse GANP in Daudi.
- the VH3-CHlCrau fragment was amplified by PCR, subcloned into plasmid, and sequenced. I is silent mutation (the amino acid remains the same), and the other symbol is a mutation in which an amino acid is substituted.
- Daudi / mock contains almost no mutations, but Daudi / GANP14, 15, 17, and 21 clones show more or less variation, albeit with varying degrees.
- the transmutation efficiency of the transfectant introduced with a mutant (GANP S / A) in which serine at position 502 related to the control of DNA primase activity is replaced with alanine decreases the efficiency of the mutation.
- FIG. 9 shows the generation of transgenic mice overexpressing GANP in B cells.
- Transgenic mice overexpressing mouse GANP under the control of the Ig Enhancer Z promoter were produced ( Figures a and b). It was confirmed by RT-PCR that GANP mRNA expression was enhanced (Fig. C).
- Figure 10 shows that GANP overexpressing transgenic (Tg) mice were immunized three times every two weeks with 50 ⁇ g of NP-CG, VH186.2 was amplified by PCR, and somatic mutations were analyzed. The results are shown. Although the number of mutations increased slightly at Tg, the mutation in which the 33rd W, which shows high affinity, was changed to L was approximately tripled at Tg.
- FIG. 11 shows production of a B cell-specific GANP-deficient mouse (B-K0). ⁇ mice in which exon 2 was inserted in the ⁇ sequence were produced and crossed with CD19-Cre mice to establish mice that lack GANP in B cells (FIGS. A and b). The absence of GANP expression in B cells was confirmed by RT-PCR and cell staining (FIGS. C and d).
- FIG. 12 shows the results of cell surface staining using B cell-specific GANP-deficient mice (B-K0). There was no difference between WT (wild type) and B-K0. The IgM + IgD + population was reduced in B-K0 lymph nodes.
- FIG. 13 shows the results of the proliferation assay. Although there was little difference, only CD40-stimulated proliferation was reduced by about half.
- FIGS. 14 to 16 show the results of measurement of antigen-specific antibody production in B-K0 mice.
- Anti-TNP antibody titer was measured by ELISA 14 days after immunization with TNP-Ficoll, a TI antigen, and there was no particular difference.
- the TD antigen, TNP-KLH showed little difference after 10 days, but was slightly higher in B-K0 after 14 days.
- Examination of germinal center (GC) formation revealed that B-K0 had slightly worse GC formation 10 days after immunization. However, after 14 days, the number of B-K0 was larger than that of WT, and GC formation was prolonged even after 20 days.
- Figures 17 and 18 show impaired affinity maturation in B-K0 mice. After immunization with 100 ⁇ g of NP-CG, NP-bound IgGl weakly positive and CD38 weakly positive were sorted as GC-B cells (Fig. 17), genomic DNA was extracted therefrom, and VH186.2 was amplified by PCR. And sequence analysis (Fig. 18). As a result, the number of mutations decreased, and the number of mutations in which the 33rd W changed to L was reduced to 1/3 in B-K0. These results indicate that GANP is essential for affinity maturation.
- Figure 19 shows that high affinity antibodies were produced using GANP transgenic mice.
- the present invention relates to a transgenic mammal into which a GAMP gene has been introduced, and the transgenic mammal can preferably express the introduced GANP gene in B cells.
- the complex formed by the GAMP gene and its related molecules is a molecule directly and indirectly required in the process of inducing mutations in the gene. Since the GANP possesses the ability to induce the induction of high-affinity mutations in the V region when repairing a gene mutation, the transgenic mammal of the present invention
- the introduction can promote the production of high affinity antibodies for acquired immunity. Also, transgenic mammals that overexpress this gene can rapidly produce antibodies with high binding power to the antigen.
- a high-affinity antibody that cannot be obtained by conventional methods can be easily obtained, and a monoclonal antibody that can eliminate intractable pathogenic microorganisms and foreign substances can be obtained. Further, by producing a human antibody using the transgenic mammal of the present invention, it is possible to dramatically increase the efficacy of antibody therapy.
- the GANP protein in the present invention is a protein having a molecular weight of 210 kDa whose amino acid sequence is specified in WO 00/50611. It has been reported that GANP protein has RNA primase activity and is involved in cell cycle regulation of B cells.
- the GANP protein and the gene encoding it are described in International Publication WOO 506111, and specifically, as SEQ ID NO: 1 or SEQ ID NO: 3 in the sequence listing of International Publication WOO / 50611. G specified by the described amino acid sequence An ANP protein and a gene encoding the same are included.
- the GANP gene may be a mutant. Specifically, in the amino acid sequence described in SEQ ID NO: 1 or SEQ ID NO: 3 in the sequence listing of International Publication WOO / 50611,-or a plurality of amino acids are missing. An RNA primer in which one or more amino acids have been replaced with another amino acid and / or one or more other amino acids have been added, and are the same as the above-mentioned GANP protein. A GANP mutein having zeta activity can also be used. Details of such a mutant gene and a method for obtaining it are described in International Publication WO00 / 50611.
- mammal in the present invention means any mammal such as a red sea lion, a buda, a goat, a gray heron, a dog, a cat, a mouse, a rat, a hamster and a guinea pig, and preferably a mouse, a gray heron, It is a rat or a hamster, particularly preferably a mouse.
- the transgenic mammal of the present invention is preferably used for embryo development during non-human mammal development with respect to unfertilized eggs, fertilized eggs, germ cells including sperm and their progenitor cells, and the like. More preferably, at the stage of a single cell or a fertilized egg cell and generally before the 8-cell stage), the calcium phosphate method, the electric pulse method, the ribofuel method, the aggregation method, the microinjection method, the particle gun method, the DEA-dextran method, and the like By introducing a GANP gene, which is a transgene, the gene can be prepared.
- the GANP gene of interest can be transferred to somatic cells, organs of living organisms, tissue cells, and the like, and used for cell culture, tissue culture, and the like.
- the transgenic animal can also be prepared by fusing with a cell blending method known per se.
- the gene When introducing the GANP gene into a target animal, it is preferable to introduce the gene as a gene construct linked downstream of a promoter that can be expressed in cells of the target animal.
- various mammals having the GANP gene of interest By injecting a vector obtained by ligating the GANP gene downstream of various promoters capable of expressing the same GANP gene into a fertilized egg of a target mammal (eg, a mouse fertilized egg), the desired GANP gene can be obtained.
- a transgenic mammal that highly expresses the gene can be produced.
- GANP gene expression vectors include Escherichia coli-derived plasmids, Bacillus subtilis-derived plasmids, yeast-derived plasmids, batter phage such as ⁇ phage, lettomouth wis / les such as Moroni monoleukemia virus, and vaccinia. Viruses or animal viruses such as baculovirus are used. Examples of the promoter that regulates gene expression include promoters of genes derived from viruses (cytomegalovirus, Moroni leukemia virus, JC virus, breast cancer virus, etc.), and mammals of various species (human, egret, dog). Genes from cats, cats, guinea pigs, hamsters, rats, mice, etc.
- birds eg, chickens
- chickens eg, albumin, insulin II, erythropoietin, endothelin, osteocalcin, muscle creatine kinase, platelet-derived growth factor ⁇ , keratin ⁇ ⁇ , ⁇ and ⁇ 14, collagen type I and type II, atrial natriuretic factor, dopamine / 3_hydroxylase, endothelial receptor oral synthase, sodium potassium adenosine 3 kinase, di-eurofilament light chain, meta-oral thionei I and ⁇ , meta-oral proteinase 1 tissue inhibitor, MHC class I antigen, smooth muscle ⁇ -actin, polypeptide chain elongation factor la (EF-1a), ⁇ -actin, ⁇ and / 3 myosin heavy chain, myosin light Chains 1 and 2, promoters of genes such as myelin-based protein, serum amyloid II component, myoglobin, and renin].
- the vector may have a terminator that terminates transcription of the messenger RNRN in the transgenic mammal.
- the splicing signal of each gene, the enhancer region, and a part of the intron of the eukaryotic gene were placed 5 'upstream of the promoter region, between the promoter region and the translation region, or Ligation 3 ′ downstream of the translation region is also possible if desired.
- the human immunoglobulin gene By linking a part of Longenhansa to the 5, side of the GANP gene, the GAMP gene can be selectively expressed in B cells.
- the GANAP gene is introduced at the fertilized egg cell stage so that it is present in excess in all germ cells and somatic cells of the target mammal.
- the excessive presence of the GNP gene in the germinal cells of the transgenic animal produced means that the offspring of the produced animal have the GANP gene excessively in all of its germ cells and somatic cells.
- the offspring of such animals that have inherited the gene have an excess of G ANP protein in all of their germinal and somatic cells.
- Fertilized eggs used to transfer an exogenous GANP gene, which is a gene different from the endogenous gene of the transgenic subject animal, to a non-human mammal (preferably a mouse or the like) or a fertilized egg of its ancestor are It is obtained by crossing male and female mammals of the same species.
- fertilized eggs can be obtained by natural mating, a method of artificially regulating the estrous cycle of a female mammal and then mating it with a male mammal is preferred.
- Methods for artificially regulating the estrous cycle of female mammals include, for example, follicle-stimulating hormone (pregnant horse serum gonadotropin (PMSG)) first, and then luteinizing hormone (human chorionic gonadotropin (hC)). G))) is preferably administered, for example, by intraperitoneal injection.
- PMSG horse serum gonadotropin
- hC human chorionic gonadotropin
- the non-human mammal having the DNA incorporating the exogenous gene can be obtained by artificially implanting and implanting the exogenous GANP gene into a female mammal.
- the fertilized eggs obtained in pseudopregnant female mammals in which fertilization has been induced are artificially implanted and mated by mating with male mammals.
- the method of flooring is preferred.
- a totipotent cell into which a gene is introduced a fertilized egg or an early embryo can be used in the case of a mouse.
- Microinjection of DNA is preferred in consideration of the yield rate of transgenic animals and the efficiency of transgene transfer to the next generation.
- the fertilized eggs into which the gene has been injected are then transplanted into the fallopian tube of the foster mother, and the animals that have developed and born are placed in foster parents and reared, and then a part of the body (in the case of mice, for example, the tail tip).
- DNA can be extracted from the DNA and the presence of the transgene can be confirmed by Southern analysis or PCR. If the individual in which the presence of the transgene is confirmed is the first generation (Founder), the transgene is transmitted to 50% of its offspring (F 1). Furthermore, by crossing the F1 individual with a wild-type animal or another F1 animal, an individual (F2) having a transgene in one (heterozygous) or both (homozygous) diploid chromosomes is created. can do.
- a transgenic mammal with a high expression of G ANP protein can also be prepared by introducing the above G ANP gene as a transgene into ES cells.
- the G ANP gene is introduced into HPRT-negative (lacking the hypoxanthanganin. Phosphoribosyltransferase) ES cells (embryonic stem cells) derived from normal mouse blastocysts (blastcyst).
- ES cells in which the G NP gene has been integrated into a mouse endogenous gene are selected by the HAT selection method.
- the selected ES cells are microinjected into fertilized eggs (blastocysts) obtained from another normal mouse.
- the blastocyst is implanted into the uterus of another normal mouse as a foster parent.
- a chimeric transgenic mouse is born from the foster parent mouse.
- a heterotransgenic mouse can be obtained.
- homotransgenic mice are obtained.
- transgenic mammals include tissues, organs and cells of the mammals.
- organs or tissues include spleen, thymus, lymph nodes, bone marrow or tonsils, and cells. Examples include B cells.
- the transgenic mammal of the present invention can also be bred to a mammal that further activates B cells, thereby producing a higher-affinity antibody.
- MRL / l P r which is an autoimmune disease mouse
- NZB x NZW mutagenesis the like
- the present inventors have also found that the GANP gene is expressed in the MRL / lpr mouse in this manner.
- the antibody in the present invention means a protein having an activity of specifically binding to an antigen, and is preferably produced by B cells.
- an antibody having high reactivity with an antigen is referred to as a high affinity antibody.
- the increased affinity of the antibody molecule is caused by the induction of somatic mutation (SHM) in the variable region (V region) gene of the antibody gene.
- SHM somatic mutation
- V region variable region gene of the antibody gene.
- SHM somatic mutation
- the antigen is administered to the living body and several times of boosting increase the binding affinity of the antibody to the antigen.
- B cells require stimulation from T cells, and it is said that activation is performed in the germinal center region of peripheral lymphoid tissues.
- RNA editing molecule AID expressed in the germinal center is required as a molecule required for mutagenesis of the V region gene.
- DNA ⁇ It has been reported that lacyl glycase and DNA polymerase required for DNA replication are involved in DNA polymerases and Iota, but the molecules controlling these functions have not yet been elucidated. .
- the GANP molecule has revealed its function as a new SHM-inducing molecule, and its increased expression is an important key to SHM induction. In particular, it proved to be important for producing high-affinity antibodies.
- the antibody induced by immunizing C57BLZ6 mice with ditrophenyl chicken gamma globulin as a hapten carrier antigen uses VH186.2 locus for the L chain and L chain for the L chain.
- the antibody obtained by the booster immunization is an IgG1 antibody.
- the mutation induced in the V region sequence of the antibody having a high binding affinity is a mutation in which the third tryptophan is mutated to leucine.
- a high-affinity V region mutation was induced in this model system, indicating that high-affinity antibodies were induced. Clear evidence at the molecular level.
- a high-affinity antibody can be produced by administering the antigen to the transgenic mammal described in (1) or a progeny thereof to produce the antibody. That is, a target antigen is administered to an animal in which the GANAP protein is highly expressed by a conventional method, and a high-affinity antibody can be prepared from spleen lymphocytes of the sensitized animal.
- the high affinity antibody may be a polyclonal or monoclonal antibody.
- a method for producing a polyclonal antibody can be obtained, for example, by administering an antigen to the transgenic mammal of the present invention, collecting blood from the mammal, and separating and purifying the antibody from the collected blood.
- the immunization method is known to those skilled in the art, and can be performed, for example, by administering the antigen one or more times.
- the antigen may be administered, for example, two to three times at intervals of 7 to 30 days.
- the dose may be, for example, about 0.05 to 2 mg at a time.
- the route of administration is not particularly limited, and subcutaneous administration, intradermal administration, intraperitoneal administration, intravenous administration, intramuscular administration, etc.
- the antigen can be appropriately selected, but injection is performed intravenously, intraperitoneally or subcutaneously.
- the antigen can be used by dissolving it in an appropriate buffer, for example, an appropriate buffer containing a commonly used adjuvant such as complete Freund's adjuvant or aluminum hydroxide, but depending on the administration route and conditions, etc. Sometimes no adjuvant is used.
- booster immunization can be performed using, for example, 100 to 100 ⁇ g of the antigen.
- blood is collected from the immunized mammal, and the blood is collected, for example, by centrifugation, precipitation using ammonium sulfate or polyethylene daricol, gel filtration chromatography, ion exchange chromatography.
- a polyclonal antibody can be obtained as a polyclonal antiserum by separation and purification by a conventional method such as chromatography, affinity chromatography, and other chromatography methods.
- the hybridoma method can be mentioned.
- a peptide constituting an antigen of interest is suspended in an adjuvant, and the suspension is administered subcutaneously or intradermally to an immunized animal (ie, the transgenic mammal of the present invention).
- the adjuvant used include Freund's complete adjuvant, Freund's incomplete adjuvant, BCG, trehalose dimycolate (TDM), lipopolysaccharide '(LPS), alum adjuvant, and silica adjuvant. It is preferable to use a combination of Freund's complete adjuvant (CFA) and Freund's incomplete adjuvant (IFA) in view of the inducibility and the like.
- CFA Freund's complete adjuvant
- IFA Freund's incomplete adjuvant
- the immunized animal be subjected to booster immunization several times after the initial immunization of the antigen, and to perform partial blood collection after an appropriate number of days to measure the antibody titer. Since the antibody produced by the method of the present invention is a high-affinity antibody, the first immunization may be sufficient.
- the antibody titer can be measured by a known method such as the ELISA method.
- the spleen is removed from the immunized animal after the sensitization, and B cells are obtained.
- B cells are high-affinity antibody-producing cells, and can be used as they are as immunostimulants. It is also possible to directly obtain V region genes and measure somatic mutations in the V region.
- the B cells are fused with myeloma cells according to a conventional method to prepare an antibody-producing hybridoma.
- HBSS Hanks' balanced salt solution
- B cells spleen Get lymphocytes
- the resulting spleen lymphocytes are stained with a trypan blue staining solution, the number of viable cells is counted, and the cells are fused with myeloma cells to obtain a hybridoma.
- the myeloma cell used is not particularly limited, and a known myeloma cell can be used.
- a known myeloma cell can be used.
- P 3—X63—Ag 8—01 (X63), P 3 -NS 1-1 -Ag 4-1 (NS l), SP 2 / O-Ag 14 (SP 2/0) Can be.
- compatibility with antibody-producing cells must be considered.
- the cell fusion method any method known in the art, such as the Sendai virus method, the polyethylene glycol method, and the protoplast method, can be arbitrarily selected and used.In particular, the polyethylene glycol method has relatively low cytotoxicity. The fusion operation is preferred because it is simple.
- the obtained hybridoma is cultured in an HAT medium (medium containing hypoxanthine, aminopterin and thymidine) for an appropriate period according to a conventional method, and a hybrid is selected. Next, after screening the desired antibody-producing hybridoma, the cloning of the hybridoma is performed.
- HAT medium medium containing hypoxanthine, aminopterin and thymidine
- a known antibody detection method can be used, and examples thereof include an enzyme immunoassay (hereinafter referred to as “ELISA”) method, a radioimmunoassay (hereinafter referred to as “RIA”) method, a plaque method, and the like.
- ELISA enzyme immunoassay
- RIA radioimmunoassay
- An agglutination reaction method or the like can be used.
- Ma as a cloning method, a method known in the art can be used. For example, a limiting dilution method, a soft agar method, a FACS method, or the like can be used.
- the obtained hybridomas are cultured in an appropriate culture medium or administered intraperitoneally to mice compatible with the hybridomas, for example.
- a desired monoclonal antibody can be isolated and purified from the thus obtained culture solution or ascites by salting out, ion exchange chromatography, gel filtration, affinity chromatography, or the like.
- an antibody fragment refers to a partial region of the above-described polyclonal or monoclonal antibody, and specifically includes [Fb) 2 , Fab, Fab, Fv (variable fragment of antibody), sFv, ds Fv (disulphide stabilised Fv)
- dAb single domain antibody
- F (ab ′) 2 ” and “Fal>” are produced by treating immunoglobulin (monoclonal antibody) with a protease such as pepsin or papine, and the like.
- An antibody fragment produced by digestion before and after a disulfide bond existing between two heavy chains.
- IgG when IgG is treated with papain, it is cleaved upstream of the disulfide bond existing between the two heavy chains in the hinge region (light chain variable region) and Ct (light chain constant region).
- ⁇ chain fragment consisting of the L chain and ⁇ ⁇ ⁇ ( ⁇ chain variable region) and C H yl ( ⁇ ⁇ region in the H chain constant region) are linked by disulfide bonds at the C-terminal region.
- Antibody fragments can be produced. Each of these two homologous antibody fragments is called Fab '.
- the fragment When IgG is treated with pepsin, the fragment is cleaved downstream of the disulfide bond existing between the two heavy chains in the hinge region, and the antibody fragment is slightly larger than the two Fab's connected by the hinge region. Can be manufactured. This antibody fragment is called F (ab,) 2 .
- the high affinity antibody of the present invention may be a humanized antibody or a human antibody. These antibodies can be used to immunize a mammal whose immune system has been replaced with that of a human to directly produce a human antibody in the same manner as a normal monoclonal antibody.
- the isotype of the antibody of the present invention is not particularly limited. For example, it may have any isotype of IgG (IgGl, IgG2, IgG3, IgG4), IgM, IgA (IgAl, IgA2), IgD or IgE.
- the high affinity antibody described in (2) above is useful as a drug for diagnosis, treatment or prevention of disease.
- the method for diagnosing various diseases using the antibody of the present invention is performed by binding a sample, for example, serum or the like, from a subject suspected of various diseases to the antibody of the present invention by an antigen-antibody reaction, and determining the amount of the bound antibody. This is performed by detecting the amount of the target antigen in the sample.
- the amount of the antibody may be detected according to a known immunoassay, and for example, immunoprecipitation, immunoagglutination, labeled immunoassay, immunoassay, immunoturbidimetry, and the like can be used.
- a labeled immunoassay is preferred in that it is simple and highly sensitive.
- the antibody titer in a sample can be expressed by the amount of label detected directly using the labeled antibody, or can be expressed relatively by using an antibody with a known concentration or known antibody titer as a standard solution. ,. That is, a standard solution and a sample are simultaneously measured by the same measurement system, and the antibody titer in the sample can be relatively expressed based on the value of the standard solution.
- the labeling immunoassay a known assay such as ELISA, RIA, fluorescence immunoassay, chemiluminescence immunoassay and the like can be arbitrarily used.
- an enzyme, a radioisotope, a fluorescent compound, a chemiluminescent compound, and the like may be appropriately selected according to the above-described measurement method.
- the enzyme include peroxidase, alkaline phosphatase, acid phosphatase, glucose oxidase and the like.
- an avidin-biotin complex as the labeling substance, the detection sensitivity of the labeling substance can be improved.
- the radioactive isotopes are mainly 1251 force.
- the fluorescent compounds include fluorescein isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (RITC). I can do it.
- chemiluminescent compounds include oral fins, luminol, and lucigenin. Labeling of the antibody with the labeling substance can be performed according to a conventional method. Hereinafter, a labeled immunoassay using a labeled antibody will be described.
- Non-competitive reaction systems require a solid phase (solid phase method).
- a solid phase is not necessarily required (liquid phase method). It is preferable to use a solid phase because the measurement operation is simplified.
- the material of the solid phase include polystyrene, nylon, glass, silicone rubber, and cellulose, and examples of the shape of the solid phase include a sphere, a well, a tube, and a sheet.
- the present invention is not limited thereto, and any known one used for the labeling immunoassay can be used arbitrarily.
- the measurement is performed by immobilizing the sample or the antibody of the present invention, reacting the sample with the antibody or the sample of the present invention, and then labeling a previously labeled anti-immunoglobulin antibody (secondary antibody). ) To react with the antibody reacting with the immobilized sample. By labeling this secondary antibody, the amount of antibody bound to the sample can be detected. The amount of the detected labeled secondary antibody is positively correlated with the amount of the target antigen in the sample, whereby the amount of the target antigen in the sample can be determined.
- secondary antibody an anti-immunoglobulin antibody
- a sample and a certain amount of the target antigen are competitively bound to a certain amount of antibody.
- the antigen of interest is added in advance and reacted with the antibody of the present invention.
- the antibody that has reacted with the immobilized sample is reacted with a pre-labeled anti-immunoglobulin antibody (secondary antibody), and the amount of the antibody can be detected using the labeling substance.
- the amount of label detected is inversely related to the amount of antigen of interest added.
- the antibody of the present invention is immobilized, reacted with a sample, and then reacted with a pre-labeled target antigen.
- the amount of label detected is inversely correlated with the amount of GANAP protein in the sample bound to the antibody.
- the solid-phase method for the antigen or antibody described above includes a physical adsorption method, a covalent bonding method, Known methods such as an on-bonding method and a crosslinking method can be used. In particular, physical adsorption is preferred because of its simplicity.
- the anti-immunoglobulin antibody (secondary antibody) for example, an anti-IgG antibody, an anti-IgM antibody and the like can be used.
- the antibody molecule may be used as it is, or Fab, Fab ', F (ab') 2 which is an antibody fragment containing an antigen-binding site obtained by enzymatically treating the antibody may be used.
- a substance having an affinity specific to the antibody molecule for example, protein A having an affinity specific to IgG, may be labeled and used.
- the labeled immunoassay include an immunoassay using an enzyme as a label, and an ELISA assay.
- a GANP protein to be detected is placed in a 96-well plate by placing a sample or a diluent thereof at room temperature at 4 ° C to room temperature or at 37 ° C for 1 to 3 hours. Adsorb and solidify. Next, the antibody of the present invention is reacted, and then an anti-immunoglobulin antibody (secondary antibody) to which an enzyme has been previously bound is reacted. Finally, an appropriate chromogenic substrate that reacts with the enzyme (for example, p-nitrophenyl phosphate if the enzyme is phosphatase) is added, and the antibody is detected by the color development.
- an appropriate chromogenic substrate that reacts with the enzyme for example, p-nitrophenyl phosphate if the enzyme is phosphatase
- the drug efficacy evaluation method using the high-affinity antibody of the present invention comprises administering a drug to various disease patients or various disease model animals, and then measuring the amount of antigen such as virus in a living body using the antibody of the present invention. By detecting and comparing the amounts, it is possible to evaluate the efficacy as a therapeutic agent for various diseases through the amount of the antigen in the living body.
- the high affinity antibody of the present invention can be provided in the form of a kit for diagnosing various diseases.
- the kit can be used for the diagnostic method of the present invention and the drug efficacy evaluation method of the present invention.
- the kit of the present invention includes at least one or more selected from the following (a) and (b).
- the antibody of the present invention or a labeled product thereof (b) Immobilized reagent on which the antibody or its label described in (a) above is immobilized.
- the labeled substance of the antibody is labeled with an enzyme, radioisotope, fluorescent compound, or chemiluminescent compound.
- Examples of the material of the solid phase for immobilizing the antibody or these labeled substances in the kit of the present invention include polystyrene, nylon, glass, silicon rubber, and cellulose, and the shape of the solid phase is spherical or pear-shaped. , A tube, a sheet and the like, but are not limited thereto.
- a solid phase and a solid phase immobilization reagent required for solid phase immobilization may be attached.
- As a solid phase reagent in the case of immobilized by e.g. physical adsorption, 50 mM carbonate buffer (pH 9. 6), 10 raM Tris - HCl buffer (. P H8 5, lOOmM sodium chloride-containing), PBS And a blocking solution containing 0.5% gelatin or the like in the coating solution, if necessary.
- the antibody in the kit of the present invention may be in a state of being dissolved in PBS or the like, or in a state of being bound to a gel (hereinafter abbreviated as “absorption gel”).
- absorption gel a gel for absorption
- An appropriate amount of the above-mentioned gel for absorption may be packaged in advance in a microcentrifuge tube of about 0.5 to 2 ml for absorption by the batch method, or a column for absorption by the column method. It may be pre-filled in a mini-column with a volume of 0.1 to 5 ml.
- the kit of the present invention includes, in addition to the above-mentioned components, other reagents for performing the detection of the present invention, for example, when the label is an enzyme label, an enzyme substrate (a chromogenic substrate, etc.), an enzyme substrate solution , An enzyme reaction stop solution, a sample diluent, or the like.
- the sample diluent include PBS (physiological phosphate buffer, pH 7.4), Tris-HCl buffer (pH 7.4 and 20 mM) containing 137 mM sodium chloride and 3 mM chloride, "TBS" is abbreviated), 0.05% Tween 20, PBS containing 0.1 to 1% BSA, or TBS.
- the sample diluent may be used for diluting an antibody, for example, in addition to diluting the sample.
- the high-affinity antibody of the present invention is also useful for treating or preventing a disease as long as it has an action of neutralizing the activity of an antigen causing a disease.
- the drug of the present invention is preferably provided in the form of a pharmaceutical composition containing the high-affinity antibody of the present invention or a fragment thereof as an active ingredient, and further containing a pharmaceutically acceptable carrier.
- “pharmaceutically acceptable carrier” refers to excipients, diluents, extenders, disintegrants, stabilizers, preservatives, buffers, emulsifiers, fragrances, coloring agents, sweeteners, thickeners. And flavoring agents, solubilizing agents or other additives.
- tablets, pills, powders, granules, injections, liquids, capsules, troches, elixirs, suspensions, emulsions or syrups can be used.
- a composition can be prepared.
- These pharmaceutical compositions can be administered orally or parenterally.
- Other forms for parenteral administration include topical solutions, suppositories and pessaries for enteral administration which contain one or more active substances and are formulated in a conventional manner.
- the dosage of the drug of the present invention varies depending on the patient's age, gender, body weight and symptoms, therapeutic effect, administration method, treatment time, type of high-affinity antibody as an active ingredient contained in the drug, and the like. Usually, it can be administered in the range of 10 / ig to 1000 rag per adult, preferably in the range of 100 mg / capita, but is not limited to this range.
- a pharmaceutically acceptable carrier such as physiological saline or commercially available distilled water for injection to a concentration of 0.1 g antibody Zml carrier to 10 mg antibody Zml carrier.
- it can be produced by suspending.
- the injection thus produced is applied to a human patient in need of treatment at a rate of 1 jug to 100 mg / kg body weight per administration, preferably 50 / g to 100 mg / kg body weight. It can be administered once to several times a day at a rate of 50 rag.
- the form of administration includes intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, intraperitoneal injection, etc., preferably intravenous injection.
- Injectables may be used as a non-aqueous diluent (eg, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, etc.), suspensions or emulsions. Prepare You can also.
- injections can be sterilized by filtration sterilization through a bacteria retaining filter, blending of a bactericide or irradiation.
- Injectables can be manufactured in the form of a fresh preparation. That is, a sterile solid composition can be prepared by freeze-drying or the like, and dissolved in sterile distilled water for injection or another solvent before use.
- the present inventors conducted an analysis after inducing GANP overexpression in a B cell tumor cell line, and as a result, it was found that the gene transfer had a remarkable effect of inducing somatic mutation of the V region gene. This effect is not seen when using a mutant gene that does not cause phosphorylation of serine at position 502 required for RNA primase, indicating that RNA primase activity is required. Is shown. This result indicates an effect of enhancing specific antibody production as a clinical auxiliary immunostimulation. It is also effective to use a retrovirus vector as a vector and to use a combination of stimulation via TNF family molecules such as CD40 and BAFF. By performing this gene transfer at the bone marrow cell level, high affinity binding in T cells can also be expected.
- the mammal overexpressing the GANP gene of the present invention is effective for developing a monoclonal antibody that is effective for preparing a biological research reagent and a clinical test reagent. For example, it is very widely applicable to easily produce a monoclonal antibody against a specific signaling molecule specifically for a functional domain or functional motif and a high-affinity antibody having a high binding force.
- the transgenic mammal of the present invention high-affinity antibody-producing cells can be selected in a short time from relatively few clones of antibodies, and the cost, time, and labor can be reduced. Is big.
- the production of phosphorylated antibodies and specific antibodies to the gene mutation portion can be applied to diagnostic agents or selective injection of drugs using antibodies. It also allows the production of high affinity antibodies that selectively bind to the nucleotide sequence of the gene.
- the antigen motif recognizes a part of the three-dimensional structure of any substance, such as inorganic substances, carbohydrates, and chemical compounds.
- mice created by crossing with autoimmune disease mice are effective in obtaining high-affinity antibodies against any antigen.
- high-affinity antibodies with a binding strength of 10-order can be produced by this method, and by introducing the technology development of the ELISA method, it is possible to develop a technology that can easily detect trace substances. is there.
- a gene therapy agent for an allergic disease or an autoimmune disease which comprises an RNA primase inactive G ANP gene.
- the gene therapy agent of the present invention can be produced by blending a recombinant vector containing an RNA primase inactive G ANP gene together with a base used for a gene therapy agent.
- the vector used in the construction of the recombinant vector include a vinoless vector such as a retrovirus vector, an adenowinores vector, an adeno-associated virus vector, a baculoinores vector, a vaccinia peninores vector, or an animal expression vector. You can also use a brass rim.
- the vector is preferably a viral vector.
- a gene therapy agent is manufactured by preparing virus particles containing recombinant DNA and blending it with the base used for the gene therapy agent be able to.
- the base used for the gene therapy agent those usually used for injections can be used.
- salt solutions such as sodium chloride or a mixture of sodium chloride and an inorganic salt, mannitol, lactose Dextran, glucose and the like; amino acid solutions such as glycine and arginine; organic acid solutions or mixed solutions of salt solutions and glucose solutions.
- these bases may be supplemented with osmotic agents, pH adjusters, vegetable oils, or surfactants, etc. according to standard methods known to those skilled in the art.
- injectables can also be prepared as solutions, suspensions and dispersions using the agents.
- These injections can also be prepared as preparations for dissolution at the time of use by operations such as powdering and freeze-drying.
- the administration form of the gene therapy agent of the present invention may be systemic administration such as usual intravenous or arterial administration, or local administration such as local injection or oral administration.
- the dosage of the gene therapy agent of the present invention varies depending on age, gender, symptoms, administration route, administration frequency, and dosage form.In general, in adults, the weight of the recombinant gene per day is from lw gZ kg to 100 OragZk. g, preferably about 10 / ig Z kg to about 100 mg / kg.
- the frequency of administration is not particularly limited.
- NZB, NZW, B / WF1, MRL / lpr, and BXSB mice were purchased from Japan SLC Co.
- C57BL / 6 and BALB mice were purchased from Charles River Japan.
- NOD mice were provided by Dr. Miyazaki of Osaka University.
- Rat monoclonal antibodies against mouse B220 (RA3-6B2), mouse IgM (AM / 3) and mouse IgD (CS / 15) were purified from culture supernatants of hybridomas and purified from D-Pyotin-N-hydroxysuccinimide. Labeled with Doestenore (Roche diagnostics, Branchburg, NJ).
- Piotin-labeled rat anti-mouse Syndecan-1 and anti-mouse CD5 monoclonal antibodies were purchased (BD PharMingen, San Diego, CA).
- Piotin-labeled peanut agglutun (PNA) was purchased from Vector Laboratories (Burlingame, CA). 3 immunity
- TNP-KLH Nitrophenyl-keyhole limpet hemocyanin
- TNP-Ficoll 100 ⁇ g of TNP-KLH emulsified in complete Freund's adjuvant or 25 ⁇ g of TNP-Ficoll in PBS was injected intraperitoneally. After 14 days, lymphoid organs were obtained and frozen with OCT compounds for immunohistochemical analysis.
- the slides were washed several times with PBS and incubated with alkaline phosphatase (ALP) -conjugated goat anti-rat IgG antibody (ICN Pharmaceuticals, Costa Mesa, CA). Color development was performed using the Vector Blue kit (Vector). For double staining, reactions were performed using a combination of a biotin-labeled antibody and horseradish peroxidase (HRP) -conjugated streptavidin (Kirkegaard & Perry Laboratories, Gaithersburg, MD). After color development with 3-3'-diaminobenzidine tetrahydrochloride (DAB; Dojindo), sections were fixed with 1% glutanrealaldehyde in PBS for 1 minute.
- ALP alkaline phosphatase
- HRP horseradish peroxidase
- DAB 3-3'-diaminobenzidine tetrahydrochloride
- GANP expression is highly expressed in highly active B cells with a tendency to autoimmunity. Lymphocytes expressing high levels of GAMP (GANP hi cells) spontaneously appear in non-immune conditions in peripheral lymph nodes of MRL / lpr mice. The increase was significant compared to C57BL / 6 mice, and no GANP hi cells were shown under non-immune conditions ( Figure 1). The appearance of the good Una G AN P M cells, was investigated in the lymph nodes of NZB mice that cause the autoimmune condition little by little during aging. Young NZB mice (7 weeks old) did not have GAN P hi cells in the popliteal lymph nodes, whereas aged NZBs (40 weeks old) had large numbers of GANP hi cells.
- GANP RNA-primase activity may play an important role in B cell activation and differentiation. Therefore, we compared the phosphorylation status of Ser 5G2 , an important phosphorylation site for RNA primase activity, using an anti-pSer 5 ° 2 monoclonal antibody in NZB mice [19].
- GANP expression was prominent at 8 weeks, and GANP M cells were detected throughout the entire period up to 32 weeks ( Figure 2; upper panel).
- pS er 5G2 although positive cells was filed in up to 8 weeks, then positive cells was significantly reduced (Fig. 2; in the middle figure). The figure shows the number of reactive cells by microscopic observation based on peak age (Fig. 2; lower panel).
- G AN P hi cells in the spleen of autoimmune-prone mice splenic red pulp are non-immune shape ⁇ I checked whether it would appear.
- the increase in GANP hi is proportional to the amount of autoantibody produced prior to the onset of autoimmune disease (FIGS. 2 and 3; Theofilopoulos AN, et al., 1985, Adv. Immunol. 37: 269-390).
- GANP hi cells Since the appearance of GANP hi cells may be associated with the B cells in autoimmune-prone mice abnormal, the appearance of GANP hi cells definitive for various autoimmune-prone mice with a non-immune conditions (8 weeks old) Examined. GANP hi cells were significantly increased in MRL / lpr, NZB and B / WF1. The number of GANP hi cells did not increase so much in BXSB and N0D of SLE-model mice, but increased when compared to control BALB mice (FIG. 4) and C57BL / 6 mice (FIG. 1). Spleen sections showed associative or immature association of PNA + B cells as GC-like structures.
- the GAN Phi cell population was further analyzed by marker analysis of lymphoid cells. They express the B220-Syndecan-II phenotype and express large amounts of IgM in cells (Figure 5). CR1, Thy - 1, and negative for GL- 7, CD23 and PNA, these results do et al, G AN P hi cells late stage of maturation B lineage cells, probably be a plasma cell shown. To determine if these cells were proliferative blast blast cells, NZB mice were injected intravenously with BrdU and spleen sections were prepared by killing after incubating for 2 hours for BrdU-incorporating cells in vivo. . GANP hi cells were not positive for BrdU incorporation (Figure 6), suggesting that these cells were not proliferative and were more mature than the plasma germ cell stage.
- Mott cells are an abnormal form of plasma cells in which large amounts of IgM molecules accumulate in rough endoplasmic reticulum-associated vesicles that are detected as cytosolic Russell bodies by PAS staining (Jiang Y., et al. 1997, J. Immunol. 158: 992-997].
- G AN P hi cells not stained with PAS- staining (Fig. 6), thereby Mott the GANP hi cells B-1 cell-derived plasma cells Can be distinguished from cells.
- LV H 3- C H 1C ⁇ transcript 5 -LV H 3 primers (5, -CTATAACCATGGACCATGGACATACTTTGTT CC- 3,) and 3 '-Xbal- C H 1- primer (5, -TGCATGCATTCTAGAGTTGCCGTTGGGGTGCTGGA C-3' ) by Amplification was performed using Pfu Turbo (Stratagene).
- the PCR product was digested with Ncol and Xbal, gel purified, and ligated with Ncol-Xbal digested plasmid. After transformation into a competent bacterium, the nucleotide sequence of a small amount of plasmid DNA prepared using the QIAprep kit (QIAGEN) was determined using an automated sequencer (Applied Biosysteras).
- the transgene was prepared by introducing a 5.6 kb mouse GAMP gene into the Xhol site of the pLG vector.
- This vector has a human immunoglobulin intron enhancer region (2 kb EcoRI fragment) and is a specific vector for strong expression in B cells.
- This gene was linearized and transfected into mice.
- a linearized pLG vector (Koike,. Et al. Int. Immunol. 7, 21-30 (1995)) containing the mouse ganp full-length cDNA was microinjected into fertilized eggs of C57BL / 6 mice.
- primer 5, -TCCCGCCTTCCAGCT GTGAC-3,
- primer 3 primer 5, -GTGCTGCTGTGTTATGTCCT-3 '
- RNA and cDNA synthesis were performed as described previously (Kuwahara, K. et al., Blood 95, 2321-2328 (2000)). GANP transcripts were detected with the two primers 1-5 'and 1-3' described above. RNA recovery was monitored using / 3-actin. 5. Establishment of CD19-Cre + / GANP flo mice
- a targeting vector was prepared by inserting a neomycin resistance gene (neo) downstream of exon II using the GNAP genome DNA.
- the ⁇ site was introduced into the intron between the 3 ′ flanking region of neo and exons I and II.
- the linearized targeting vector was transfected into TT2 ES cells (Yagi, T. et al. Anal. Biochem. 214, 70-76 (1993)) by electroporation. After selection with G418, ES colonies were picked up and incubated with proteinase K.
- the homologous recombinants were screened with neo2 primer (5'-GCCTGCTTGCCGAATATCATGGTGGAAAAT-3 ') and CGK3'-2 primer (5'-GGCACCAAGCATGCACGGAGTACACAGA-3'). Homologous recombination was confirmed by Southern blot analysis of the DNA of the ES clone digested with BamHI using probe A. Using three positive clones showing a 4 kb band, chimeric primary mice were produced by microinjection into ICR blastocysts. Mating GAN P-floxed mouse with CD19—Cre knock-in mouse (Rickert, RC, et al., Nucleic Acids Res. 25, 1317-1318 (1997)) for cells lacking the ganp gene in B cells did.
- Spleen cells were isolated from wild-type and GANP- mice (7-8 weeks old) Red blood cells were removed by treatment with 0.15 M ammonium chloride buffer. After 30 minutes incubation at 37 ° C on a plastic dish, unadhered cells are collected as lymphocytes, and T cells are collected using Dynabeads-anti-mouse Thyl. 2 monoclonal antibody (Dynal) according to the attached protocol. Removed. The purity of B cells (90% or more) was confirmed by cell surface staining using FITC-conjugated anti-B220 monoclonal antibody (BD Pharmingen).
- Purified B cells are converted to RPMI-1640 medium containing 10% heat-inactivated FCS (JRH Biosciences;), 2 raM L-glutamine and 5 x 10 " 5 M 2-mercaptoethanol (including mitogens). And without) in a 96-well microtiter plate for 48 hours in 2 ⁇ 10 5 cells Zell. Cells were incubated with 0.2 ⁇ Ci / well [3 ⁇ 4] -thymidine (ICN). The cells were recovered after pulsing for 16 hours, and the incorporated radioactivity was measured with a scintillation counter.
- TNP-KLH, TNP-Ficoll and NP-CG were purchased from Biosearch Technologies. 50 ⁇ g of TNP-KLH and NP-CG (precipitated with aluminum) or 25 g of TNP-Ficoll (dissolved in PBS) were injected intraperitoneally into wild-type and GANAP mice.
- Serum was collected from the immunized mice 10 and 14 days after challenge.
- ELISA plates were coated with 5 / g Nowell TNP-BSA (Biosearch Technology). Each well was blocked with 3% BSA in PBS and incubated with serially diluted serum. After washing with PBS-0.1% Tween 20, the wells were incubated with a biotin-conjugated isotype-specific monoclonal antibody and Streptavidin conjugated with an alkaline phosphatase (Southern Biotechnology). Color development in the presence of substrate went.
- NIP-conjugated IgGl ⁇ CDSS ⁇ B cells of mice immunized with NP-CG were fractionated by FACS Vantage (Becton Dickinson) and incubated with proteinase K at 37 ° C for 10 days. Using the lysate, PCR was performed twice as previously reported (Takahashi, Y., et al. Immunity 14, 181-192 (2001)). VH gene cDNAs were ligated into pBluescript and sequenced by an automatic sequencer.
- Somatic mutation (SHM) of V region gene of transfectant which stably expressed mouse GANP in Daudi
- the GAMP gene was introduced into various human B lymphocyte cells used for the analysis of SHM in vitro (Rogozin, IB, et al., Nat. Immunol. 2, 530-536 (2001); Kuwahara, K et al. Blood 95, 2321-2328 (2000); and Denepoux, S. et al., Immunity 6, 35-46 (1997)). Many B cell lines could not be transfected, but the ganp gene could be introduced into Daudi B cells expressing AID, which does not normally produce SHM during maintenance. This clone showed a higher frequency of SHM (5xl (T 4 / bp) in the V-region compared to wild-type and mock-transfected cells. SHM was not induced by the constant region gene.
- Sex IgG ( ⁇ 1 ⁇ 1) ⁇ ⁇ —Response
- the SHM shows a special pattern. Sequence analysis of whole spleen B cells after immunization with NP-CG showed a slight increase in the frequency of SHM in GAMP-Tg mice compared to wild-type mice (FIG. 10). ). This mouse showed a third increase in SHM from W to L (33 fold). This mutation has previously been shown to be important for affinity maturation of hapten-specific B cells
- RNA-primase GANP we used the Cre- ⁇ system to generate GANP-B-mouse that targeted CD19 + B cells and deleted the GANP gene (a and b in Figure 11).
- Floxed B cells do not express GANP mRNA (c in FIG. 11) and, according to immunostaining, express little protein (d in FIG. 11).
- GANP— ⁇ ⁇ -mice grew normally and showed normal numbers of lymphocytes in bone marrow, spleen, and lymph nodes. Flow cytometry analysis showed a normal staining profile for surface markers on bone marrow, thymus and spleen cells (Figure 12).
- TNP tri-nitrophenyl
- TD-Ags such as ⁇ -keyhole limpet hemocyanin (KLH) and NP-CG
- mutant mice showed delayed GC formation compared to wild type.
- GANP B-mice showed a gradual increase and expansion of GC on day 14 after immunization with force TNP-KLH that did not show a clear GC until day 10 (FIG. 15).
- IgM locus was not different compared to wild type. Therefore, Ag-binding IgGl B cells were purified as shown in FIG. 17 and the sequences of VH 186.2 were compared (FIG. 18).
- the overall mutation of the IgV-region sequence of GANP B-mouse was the same as that of wild-type, but the high affinity mutation from W33 to L (C57BL / 6 mouse Was significantly reduced in the mutant mice.
- the results for GANP- ⁇ - ⁇ and GANP-Tg mice demonstrate that GANP is involved in the generation of high affinity B cells after immunization with TD-Ag.
- the role of G ANP may be to mediate the efficient recruitment and regulation of DNA polymerase in GC-B cells. If GC-B cells with V-region SHMs acquire high-affinity BCRs, they should be selected, and further SHM in V-regions of B cells is suppressed, producing high-affinity antibodies in vivo Should be guaranteed. Modulation of AID activity may be necessary to maintain high affinity BCR in B cells, since expression of AID in GC-B cells can constantly generate DNA mutations. GA NP B-mice results indicate that GANP is required for the SHM process.
- a mouse overexpressing GANAP By using a mouse overexpressing GANAP according to the present invention, it is possible to quickly produce a high-affinity antibody specific to a virus antigen that could not be obtained conventionally. Therefore, it is expected that a specific and powerful antibody can be promptly obtained without delaying the deterioration of the disease state due to a prolonged infection such as AIDS or hepatitis C without being delayed by the mutation of the virus antigen. In addition, this makes it possible to prepare a tailor-made specific antibody corresponding to a mutation of a virus antigen from an infected patient. An immunization period of about 10 days is sufficient for the production of monoclonal antibodies, of which the production efficiency of antibodies with high-affinity mutations is close to 60%. High-affinity antibody production protocols using bedside patient samples are expected to be a new immunotherapy alternative to vaccine therapy.
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002343870A AU2002343870A1 (en) | 2002-11-07 | 2002-11-07 | Transgenic mammal carrying ganp and utilization thereof |
PCT/JP2002/011598 WO2004040969A1 (ja) | 2002-11-07 | 2002-11-07 | Ganp導入トランスジェニック哺乳動物及びその利用 |
CN2007101939159A CN101240291B (zh) | 2002-11-07 | 2003-11-07 | 导入ganp基因的转基因哺乳动物及其应用 |
AT03810668T ATE427654T1 (de) | 2002-11-07 | 2003-11-07 | Transgenes saugetier, das in dieses eingebrachte ganp-gene tragt, sowie seine verwendung |
CA2504867A CA2504867C (en) | 2002-11-07 | 2003-11-07 | Transgenic mammal carrying ganp gene transferred thereinto and utilization thereof |
AU2003277620A AU2003277620B2 (en) | 2002-11-07 | 2003-11-07 | Transgenic mammal carrying GANP gene transferred thereinto and utilization thereof |
KR1020057004314A KR100941905B1 (ko) | 2002-11-07 | 2003-11-07 | Ganp 유전자 도입 트랜스제닉 포유동물 및 그 이용 |
CNB2003801028324A CN100396699C (zh) | 2002-11-07 | 2003-11-07 | 导入ganp基因的转基因哺乳动物及其应用 |
US10/534,043 US7919674B2 (en) | 2002-11-07 | 2003-11-07 | Transgenic mammal carrying GANP gene transferred thereinto and utilization thereof |
EP03810668A EP1559318B1 (en) | 2002-11-07 | 2003-11-07 | Transgenic mammal carrying ganp gene transferred thereinto and utilization thereof |
DE60327094T DE60327094D1 (de) | 2002-11-07 | 2003-11-07 | Transgenes säugetier, das in dieses eingebrachte ganp-gene trägt, sowie seine verwendung |
PCT/JP2003/014221 WO2004040971A1 (ja) | 2002-11-07 | 2003-11-07 | Ganp遺伝子導入トランスジェニック哺乳動物及びその利用 |
JP2004549646A JP4478577B2 (ja) | 2002-11-07 | 2003-11-07 | Ganp遺伝子導入トランスジェニック哺乳動物及びその利用 |
US11/889,950 US20080233109A1 (en) | 2002-11-07 | 2007-08-17 | Transgenic mammal carrying GANP gene transferred thereinto and utilization thereof |
HK09101102.4A HK1124363A1 (en) | 2002-11-07 | 2009-02-06 | Transgenic mammal carrying ganp gene transferred thereinto and utilization thereof |
JP2010028977A JP5080597B2 (ja) | 2002-11-07 | 2010-02-12 | Ganp遺伝子導入トランスジェニック哺乳動物及びその利用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2002/011598 WO2004040969A1 (ja) | 2002-11-07 | 2002-11-07 | Ganp導入トランスジェニック哺乳動物及びその利用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004040969A1 true WO2004040969A1 (ja) | 2004-05-21 |
Family
ID=32310234
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/011598 WO2004040969A1 (ja) | 2002-11-07 | 2002-11-07 | Ganp導入トランスジェニック哺乳動物及びその利用 |
PCT/JP2003/014221 WO2004040971A1 (ja) | 2002-11-07 | 2003-11-07 | Ganp遺伝子導入トランスジェニック哺乳動物及びその利用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/014221 WO2004040971A1 (ja) | 2002-11-07 | 2003-11-07 | Ganp遺伝子導入トランスジェニック哺乳動物及びその利用 |
Country Status (11)
Country | Link |
---|---|
US (2) | US7919674B2 (ja) |
EP (1) | EP1559318B1 (ja) |
JP (1) | JP4478577B2 (ja) |
KR (1) | KR100941905B1 (ja) |
CN (2) | CN100396699C (ja) |
AT (1) | ATE427654T1 (ja) |
AU (2) | AU2002343870A1 (ja) |
CA (1) | CA2504867C (ja) |
DE (1) | DE60327094D1 (ja) |
HK (1) | HK1124363A1 (ja) |
WO (2) | WO2004040969A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5028020B2 (ja) * | 2005-09-30 | 2012-09-19 | 株式会社トランスジェニック | N1,n8−ジアセチルスペルミジンに対する高特異性モノクローナル抗体 |
JP5628130B2 (ja) * | 2005-09-30 | 2014-11-19 | 株式会社トランスジェニック | N1,n8−ジアセチルスペルミジンに対する高特異性モノクローナル抗体 |
PT2540820T (pt) * | 2005-12-09 | 2018-03-02 | Academisch Medisch Centrum Bij De Univ Van Amsterdam | Meios e métodos para influenciar a establidade de células produtoras de anticorpos |
JP4982847B2 (ja) * | 2006-07-10 | 2012-07-25 | 国立大学法人 熊本大学 | Ganpによる癌抑制遺伝子の活性化方法 |
JP5716257B2 (ja) * | 2009-02-06 | 2015-05-13 | 国立大学法人 熊本大学 | 胆管癌特異的糖鎖エピトープを認識するモノクローナル抗体 |
CN103429615B (zh) * | 2010-12-02 | 2018-03-16 | 埃姆医疗有限公司 | 用于生产高亲和力抗体的方式和方法 |
US9644026B2 (en) * | 2011-09-09 | 2017-05-09 | Trans Genic Inc. | Antibody against mutant α-actinin-4 |
JP6345596B2 (ja) * | 2012-10-04 | 2018-06-20 | 国立大学法人京都大学 | 原発性アルドステロン症の検出方法及びモノクローナル抗体 |
JP6462632B2 (ja) * | 2016-06-01 | 2019-01-30 | 株式会社トランスジェニック | 変異型α−アクチニン−4に対する抗体 |
US11008566B2 (en) | 2016-09-30 | 2021-05-18 | Chiome Bioscience Inc. | Method for obtaining antibody |
DK3581645T3 (da) | 2017-02-10 | 2021-11-15 | Chiome Bioscience Inc | Fremgangsmåde til at fremme diversifikation af en antistof variabel region |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000050611A1 (fr) * | 1999-02-24 | 2000-08-31 | Sumitomo Electric Industries, Ltd. | Proteines ganp |
US6372955B1 (en) * | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4418110A (en) | 1982-06-21 | 1983-11-29 | Minnesota Mining And Manufacturing | Vapor-permeable retroreflective sheeting |
NZ335759A (en) * | 1997-09-24 | 2002-02-01 | Sankyo Co | Method of diagnosing metabolic bone diseases by measuring osteoclastgenesis inhibitory factor (OCIF) |
US6972125B2 (en) * | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
JP2001078779A (ja) * | 1999-09-17 | 2001-03-27 | Sumitomo Electric Ind Ltd | Calpp蛋白質、これをコードするポリヌクレオチドおよび抗体 |
GB0010191D0 (en) * | 2000-04-26 | 2000-06-14 | Cancer Res Campaign Tech | Assays, methods and means |
-
2002
- 2002-11-07 WO PCT/JP2002/011598 patent/WO2004040969A1/ja not_active Application Discontinuation
- 2002-11-07 AU AU2002343870A patent/AU2002343870A1/en not_active Abandoned
-
2003
- 2003-11-07 AU AU2003277620A patent/AU2003277620B2/en not_active Expired
- 2003-11-07 DE DE60327094T patent/DE60327094D1/de not_active Expired - Lifetime
- 2003-11-07 CN CNB2003801028324A patent/CN100396699C/zh not_active Expired - Lifetime
- 2003-11-07 KR KR1020057004314A patent/KR100941905B1/ko active IP Right Grant
- 2003-11-07 AT AT03810668T patent/ATE427654T1/de not_active IP Right Cessation
- 2003-11-07 US US10/534,043 patent/US7919674B2/en not_active Expired - Lifetime
- 2003-11-07 WO PCT/JP2003/014221 patent/WO2004040971A1/ja active Application Filing
- 2003-11-07 JP JP2004549646A patent/JP4478577B2/ja not_active Expired - Lifetime
- 2003-11-07 CA CA2504867A patent/CA2504867C/en not_active Expired - Lifetime
- 2003-11-07 CN CN2007101939159A patent/CN101240291B/zh not_active Expired - Lifetime
- 2003-11-07 EP EP03810668A patent/EP1559318B1/en not_active Expired - Lifetime
-
2007
- 2007-08-17 US US11/889,950 patent/US20080233109A1/en not_active Abandoned
-
2009
- 2009-02-06 HK HK09101102.4A patent/HK1124363A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372955B1 (en) * | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
WO2000050611A1 (fr) * | 1999-02-24 | 2000-08-31 | Sumitomo Electric Industries, Ltd. | Proteines ganp |
Non-Patent Citations (4)
Title |
---|
FUJIMURA SATORU M.D. ET AL, CLINICAL IMMUNOLOGY, vol. 37, no. 4, 2002, pages 421 - 425, XP002980125 * |
KUWAHARA K. ET AL, PROC. NATL. ACAD. SCI. USA, vol. 98, no. 18, 2001, pages 10279 - 10283, XP002980124 * |
MAGARI M. ET AL, EUR. J. IMMUNOL., vol. 32, 2002, pages 957 - 966, XP002980127 * |
YASUDA J. ET AL, JIKKEN IGAKU BESSATSU SHINTEI SHIN IDENSHI KOGAKU HANDBOOK KAITEI DAI 3 BAN, 1999, pages 234 - 238, XP002980126 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002343870A1 (en) | 2004-06-07 |
CN101240291B (zh) | 2011-08-24 |
ATE427654T1 (de) | 2009-04-15 |
AU2003277620B2 (en) | 2008-10-16 |
HK1124363A1 (en) | 2009-07-10 |
CN101240291A (zh) | 2008-08-13 |
WO2004040971A1 (ja) | 2004-05-21 |
US7919674B2 (en) | 2011-04-05 |
CA2504867A1 (en) | 2004-05-21 |
DE60327094D1 (de) | 2009-05-20 |
JP4478577B2 (ja) | 2010-06-09 |
EP1559318A1 (en) | 2005-08-03 |
JPWO2004040971A1 (ja) | 2006-03-02 |
KR100941905B1 (ko) | 2010-02-11 |
US20060236417A1 (en) | 2006-10-19 |
CN100396699C (zh) | 2008-06-25 |
US20080233109A1 (en) | 2008-09-25 |
KR20050049490A (ko) | 2005-05-25 |
EP1559318A4 (en) | 2006-04-26 |
AU2003277620A1 (en) | 2004-06-07 |
EP1559318B1 (en) | 2009-04-08 |
CN1711018A (zh) | 2005-12-21 |
CA2504867C (en) | 2013-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7022803B2 (ja) | 限定された免疫グロブリン重鎖のマウス | |
US11230697B2 (en) | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals | |
JP6843953B2 (ja) | 動物モデル及び治療用分子 | |
JP5184374B2 (ja) | 対立遺伝子排除 | |
JP2019047806A (ja) | ヒト化軽鎖マウス | |
JP6621750B2 (ja) | ヒスチジン操作軽鎖抗体およびそれを生成するための遺伝子改変非ヒト動物 | |
US20080233109A1 (en) | Transgenic mammal carrying GANP gene transferred thereinto and utilization thereof | |
JP2017537653A (ja) | トランスジェニックマウス | |
KR20110020860A (ko) | 유전자 삽입동물에서 단일 vl 도메인 항체를 생산하는 방법 | |
US8629317B2 (en) | Non-human transgenic mammal for the constant region of the class a human immunoglobulin heavy chain and applications thereof | |
US10370641B2 (en) | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals | |
JP4568896B2 (ja) | 抗hiv抗体 | |
JP5080597B2 (ja) | Ganp遺伝子導入トランスジェニック哺乳動物及びその利用 | |
JP2012519001A (ja) | Cεへの免疫グロブリン重鎖クラススイッチングが増強された高IgE動物モデル |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |